We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+59.91%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$255M
AUM Growth
-$103M
Cap. Flow
-$140M
Cap. Flow %
-54.73%
Top 10 Hldgs %
45.35%
Holding
89
New
26
Increased
17
Reduced
12
Closed
26

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.51M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$6.07M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.74M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$3.67M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$3.24M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$12.9M
2
SNY icon
Sanofi
SNY
+$11.4M
3
ESTA icon
Establishment Labs
ESTA
+$8.21M
4
KURA icon
Kura Oncology
KURA
+$5.92M
5
AZN icon
AstraZeneca
AZN
+$5.64M

Sector Composition

Rank Sector Weight
1 Healthcare 81.4%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LNTH icon
26
Lantheus
LNTH
$6.8B
$3.09M 1.21%
60,630
-69,370
-53% -$4.28M
PCVX icon
27
Vaxcyte
PCVX
$8.01B
$2.88M 1.13%
+60,000
New +$2.35M
VRNA
28
CALL
DELISTED
Verona Pharma
VRNA
$2.74M 1.08%
+105,000
New +$1.4M
GERN icon
29
PUT
Geron
GERN
$924M
$2.56M 1%
1,056,500
+406,500
+63% +$911K
SNDX icon
30
Syndax Pharmaceuticals
SNDX
$1.98B
$2.54M 1%
+100,000
New +$2.33M
IOVA icon
31
Iovance Biotherapeutics
IOVA
$2.24B
$2.4M 0.94%
+375,000
New +$2.93M
VKTX icon
32
CALL
Viking Therapeutics
VKTX
$4.22B
$2.35M 0.92%
+250,000
New +$1.12M
KPTI icon
33
Karyopharm Therapeutics
KPTI
$169M
$2.25M 0.88%
+44,084
New +$3.06M
COGT icon
34
Cogent Biosciences
COGT
$6.54B
$2.23M 0.88%
193,064
+38,977
+25% +$483K
PNT
35
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$2.21M 0.87%
303,218
-443,358
-59% -$3.29M
NVAX icon
36
PUT
Novavax
NVAX
$1.3B
$2.06M 0.81%
+200,000
New +$3.53M
GERN icon
37
CALL
Geron
GERN
$924M
$2.03M 0.79%
837,000
+211,000
+34% +$473K
XENE icon
38
Xenon Pharmaceuticals
XENE
$6.38B
$1.97M 0.77%
+50,000
New +$1.82M
ARGX icon
39
argenx
ARGX
$52.9B
$1.89M 0.74%
+5,000
New +$1.87M
NVCR icon
40
CALL
NovoCure
NVCR
$1.85B
$1.83M 0.72%
+25,000
New +$1.88M
ALPN
41
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.82M 0.71%
247,891
+137,891
+125% +$881K
VINC
42
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.52M 0.6%
74,639
– –
CNTA
43
DELISTED
Centessa Pharmaceuticals
CNTA
$1.43M 0.56%
460,328
+217,811
+90% +$807K
KALV
44
DELISTED
KalVista Pharmaceuticals
KALV
$1.27M 0.5%
188,292
+91,974
+95% +$493K
BCAB icon
45
BioAtla
BCAB
$6.14M
$1.24M 0.49%
+3,000
New +$1.24M
DYN icon
46
Dyne Therapeutics
DYN
$3.88B
$1.07M 0.42%
+92,170
New +$1.07M
LIAN
47
DELISTED
LianBio American Depositary Shares
LIAN
$1.07M 0.42%
650,000
+100,000
+18% +$156K
NRIX icon
48
Nurix Therapeutics
NRIX
$2.36B
$878K 0.34%
+80,000
New +$965K
MIRM icon
49
Mirum Pharmaceuticals
MIRM
$7.11B
$780K 0.31%
+40,000
New +$791K
FHTX icon
50
Foghorn Therapeutics
FHTX
$305M
$702K 0.28%
+109,991
New +$829K
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Affinity Asset Advisors held 89 positions worth $255M, down 29% from $358M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Affinity Asset Advisors withdrew a net $140M in Q4 2022, closing 26 positions and reducing 12 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $12.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 51% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in BioMarin Pharmaceuticals worth $8.28M.

  • Affinity Asset Advisors's largest Q4 2022 buy was BioMarin Pharmaceuticals: 80,000 shares worth $8.28M.
  • Affinity Asset Advisors added most to Morphic Holding, Inc. Common Stock in Q4 2022, an estimated $3.67M increase.
  • Affinity Asset Advisors's biggest Q4 2022 reduction was Establishment Labs, cutting an estimated $8.21M.
  • Affinity Asset Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $12.9M.
  • Affinity Asset Advisors's ten largest holdings make up 45% of its $255M portfolio in Q4 2022.
  • Affinity Asset Advisors opened 26 new positions and closed 26 in Q4 2022.
  • Affinity Asset Advisors's portfolio value fell 29% quarter-over-quarter to $255M.

Based on Affinity Asset Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.